Title:
SECRETED ALPHA-HELICAL PROTEIN-36
Document Type and Number:
WIPO Patent Application WO/2001/000664
Kind Code:
A2
Abstract:
The present invention relates to polynucleotide and polypeptide molecules for mammalian secreted alpha helical protein-36 (Zalpha36). The polypeptides, and polynucleotides encoding them, are hormonal and may be used to regulate the functioning of the immune system. The present invention also includes antibodies to the Zalpha36 polypeptides. The Zalpha36 protein can be used to stimulate the production of leukocytes and to inhibit the production of platelets.
More Like This:
| WO/2000/071713 | VASCULAR ENDOTHELIAL GROWTH FACTOR VARIANTS |
| WO/2023/064793 | INTERLEUKIN 7 AND INTERLEUKIN 21 FUSION PROTEINS |
| JP2766621 | [Title of Invention] Recombinant G-CSF |
Inventors:
CONKLIN DARRELL C
GAO ZEREN
HEFFERNAN JANE K
MCKERNAN PATRICIA A
GAO ZEREN
HEFFERNAN JANE K
MCKERNAN PATRICIA A
Application Number:
PCT/US2000/017698
Publication Date:
January 04, 2001
Filing Date:
June 28, 2000
Export Citation:
Assignee:
ZYMOGENETICS INC (US)
International Classes:
C07K14/52; A61K38/00; A61K39/00; A61K48/00; (IPC1-7): C07K14/00
Other References:
DATABASE EMBL [Online] AF1250996, accession number AF125096, 28 June 1999 (1999-06-28) M.YE ET AL: "Human HSPCmRNA, complete cds" XP002158469 & UNPUBLISHED,
DATABASE EMBL [Online] 764222, accession number AA764222, 28 January 1998 (1998-01-28) M. MARRA ET AL: "The WashU-HHMI mouse EST project. vv45g03.r1 Soares 2NbMT musculus cDNA clone IMAGE:1225396 5', mRNA sequence" XP002158470 & UNPUBLISHED,
DATABASE EMBL [Online] HSAA82767, accession number AA082767, 29 November 1996 (1996-11-29) L. HILLIER ET AL: "zn41a02.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone IMAGE:549962 5', mRNA sequence" XP002158471 & L. HILLIER ET AL: "Generation and analysis of 280,000 human expressed sequence tags" GENOME RESEARCH , vol. 6, no. 9, 1996, pages 807-828, XP000914615
DATABASE EMBL [Online] entry AA590825, accession number AA590825, 18 September 1997 (1997-09-18) M. MARRA ET AL: "The WashU-HHMI mouse EST project" XP002158476 & UNPUBLISHED,
DATABASE EMBL [Online] C78443, accession number c78443, 13 October 1997 (1997-10-13) M.S.H. KO ET AL: "Mus musculus 3.5-dpc blastocyst cDNA 3'-end sequence" XP002158473 & UNPUBLISHED,
DATABASE EMBL [Online] 764222, accession number AA764222, 28 January 1998 (1998-01-28) M. MARRA ET AL: "The WashU-HHMI mouse EST project. vv45g03.r1 Soares 2NbMT musculus cDNA clone IMAGE:1225396 5', mRNA sequence" XP002158470 & UNPUBLISHED,
DATABASE EMBL [Online] HSAA82767, accession number AA082767, 29 November 1996 (1996-11-29) L. HILLIER ET AL: "zn41a02.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone IMAGE:549962 5', mRNA sequence" XP002158471 & L. HILLIER ET AL: "Generation and analysis of 280,000 human expressed sequence tags" GENOME RESEARCH , vol. 6, no. 9, 1996, pages 807-828, XP000914615
DATABASE EMBL [Online] entry AA590825, accession number AA590825, 18 September 1997 (1997-09-18) M. MARRA ET AL: "The WashU-HHMI mouse EST project" XP002158476 & UNPUBLISHED,
DATABASE EMBL [Online] C78443, accession number c78443, 13 October 1997 (1997-10-13) M.S.H. KO ET AL: "Mus musculus 3.5-dpc blastocyst cDNA 3'-end sequence" XP002158473 & UNPUBLISHED,
Attorney, Agent or Firm:
Lunn, Paul G. (Inc. 1201 Eastlake Avenue East Seattle, WA, US)
Download PDF:
Claims:
CLAIMS What is claimed is:
| 1. | A polypeptide comprised of a sequence selected from the group consisting of SEQ ID NOs. 2, 3, 5 and 6. |
| 2. | An isolated polynucleotide that encodes a polypeptide selected from the group of SEQ ID NOs. 2,3,5 and 6. |
| 3. | An antibody that specifically binds to a polypeptide selected from the group of SEQ ID NOs. 2,3,5 and 6. |
| 4. | A method for inducing the proliferation of leukocytes comprising administering a therapeutically effective amount of Zalpha36. |
| 5. | A method for inducing the proliferation of platelets comprising administering a therapeutically effective amount of an antagonist to Zalpha36. |
| 6. | The method of claim 5 wherein the antagonist is an antibody to Zalpha36. |
| 7. | A method for inhibiting the production of platelets comprising administering a therapeutically effective amount of Zalpha36. |
| 8. | An educational kit comprised of a polynucleotide that encodes Zalpha36. |
| 9. | The educational kit of claim 8 further comprising a Zalpha36 protein. |
| 10. | The educational kit of claim 8 further comprising an antibody that specifically binds to Zalpha36. |
| 11. | The use of a Zalpha36 polypeptide in the manufacture of a medicament to stimulate the production of leukocytes. |
| 12. | The use of a Zalpha36 polypeptide in the manufacture of a medicament to inhibit the production of platelets. |
| 13. | The use of an antagonist to a Zalpha36 polypeptide in the manufacture of a medicament to stimulate the production of platelets. |
| 14. | The use of claim 13 wherein the antagonist is an antibody to a Zalpha36 polypeptide. SEQUENCE LISTING <110> ZymoGenetics, Inc.. <120> Mammalian alpha helical protein36 <130> 9942 <150>09/343,152 <151> 19990628 <160> 26 <170> FastSEQ for Windows Version 3.0 <210> 1 <211> 1098 <212> DNA <213> Homo sapiens <220> <221> CDS <222> (33)... (629) <400> 1 gcgctgccgg gtgaaatcgt aggacagtga ag atg ctg ctg gaa ttg tcc gag 53 Met Leu Leu Glu Leu Ser Glu 1 5 gag cat aag gaa cac ctg gcc ttc ctg cct caa gtg gac agc gcg gtg 101 Glu His Lys Glu His Leu Ala Phe Leu Pro Gln Val Asp Ser Ala Val 10 15 20 gtc gcc gag ttt ggg cgg att gct gtg gaa ttc ctg aga cgc ggc gca 149 Val Ala Glu Phe Gly Arg Ile Ala Val Glu Phe Leu Arg Arg Gly Ala 25 30 35 aac cca aaa atc tac gaa ggc gcc gcc aga aaa ctc aat gtg agt agt 197 Asn Pro Lys Ile Tyr Glu Gly Ala Ala Arg Lys Leu Asn Val Ser Ser 40 45 50 55 gac act gtc cag cat ggt gtg gaa gga tta acg tat ctc ctc act gag 245 Asp Thr Val Gln His Gly Val Glu Gly Leu Thr Tyr Leu Leu Thr Glu 60 65 70 agc tca aag ctc atg att tct gaa ctg gat ttc caa gac tct gtt ttt 293 Ser Ser Lys Leu Met Ile Ser Glu Leu Asp Phe Gln Asp Ser Val Phe 75 80 85 gtt ctg gga ttc tct gaa gaa tta aac aaa ttg ttg ctt cag ctt tat 341 Val Leu Gly Phe Ser Glu Glu Leu Asn Lys Leu Leu Leu Gln Leu Tyr 90 95 100 ctg gac aac aga aaa gag atc aga acg ctt ctg agt gaa ttg gca cca 389 Leu Asp Asn Arg Lys Glu Ile Arg Thr Leu Leu Ser Glu Leu Ala Pro 105 110 115 agc ctt ccc agt tat cat aac ctt gaa tgg cga cta gat gta cag ctt 437 Ser Leu Pro Ser Tyr His Asn Leu Glu Trp Arg Leu Asp Val Gln Leu 120 125 130 135 gca agt aga agt ctc agg caa cag att aaa cca gca gtg act ata aag 485 Ala Ser Arg Ser Leu Arg Gln Gln Ile Lys Pro Ala Val Thr Ile Lys 140 145 150 cta cac ctt aat caa aat gga gat cac aac acc aaa gtt ctg cag aca 533 Leu His Leu Asn Gln Asn Gly Asp His Asn Thr Lys Val Leu Gln Thr 155 160 165 gac cca gcc acc ctg ctc cat ttg gtt caa caa ctg gaa caa gca ttg 581 Asp Pro Ala Thr Leu Leu His Leu Val Gln Gln Leu Glu Gln Ala Leu 170 175 180 gaa gag atg aag aca aac cac tgt agg aga gtt gtt cgc aac atc aag 629 Glu Glu Met Lys Thr Asn His Cys Arg Arg Val Val Arg Asn Ile Lys 185 190 195 tagtaccagt tttaaggttt taattcattt gaatcactta tgaattgatg atatacagca 689 attacttttc aaaattaatt ttttattaat tcatgatgat aaatacatag tattcctcag 749 tatctattcc aagatactga ggtcataatc agaagctaag ctgggtgcag tggctcatgc 809 cagttatccc agcactttgg gaggccgagg tgggcaaatc atgaggtcag gagattgaga 869 ccttcctggc taacatggtg aaaccccatc tctactaaaa atataaaaaa ttagccaggt 929 gtggtggcac gcatctatca gagtcccagc tactcaggag gctgaggcag gagaatcgct 989 tgaacctggg aggtggaggt tgcagtgagc tgagattgtg ccactgcact ccagcctggg 1049 tgacagagtg agactccatc tcaaaaataa taataataat aataaagta 1098 <210> 2 <211> 199 <212> PRT <213> Homo sapiens <400> 2 Met Leu Leu Glu Leu Ser Glu Glu His Lys Glu His Leu Ala Phe Leu 1 5 10 15 Pro Gln Val Asp Ser Ala Val Val Ala Glu Phe Gly Arg Ile Ala Val 20 25 30 Glu Phe Leu Arg Arg Gly Ala Asn Pro Lys Ile Tyr Glu Gly Ala Ala 35 40 45 Arg Lys Leu Asn Val Ser Ser Asp Thr Val Gln His Gly Val Glu Gly 50 55 60 Leu Thr Tyr Leu Leu Thr Glu Ser Ser Lys Leu Met Ile Ser Glu Leu 65 70 75 80 Asp Phe Gln Asp Ser Val Phe Val Leu Gly Phe Ser Glu Glu Leu Asn 85 90 95 Lys Leu Leu Leu Gln Leu Tyr Leu Asp Asn Arg Lys Glu Ile Arg Thr 100 105 110 Leu Leu Ser Glu Leu Ala Pro Ser Leu Pro Ser Tyr His Asn Leu Glu 115 120 125 Trp Arg Leu Asp Val Gln Leu Ala Ser Arg Ser Leu Arg Gln Gln Ile 130 135 140 Lys Pro Ala Val Thr Ile Lys Leu His Leu Asn Gln Asn Gly Asp His 145 150 155 160 Asn Thr Lys Val Leu Gln Thr Asp Pro Ala Thr Leu Leu His Leu Val 165 170 175 Gln Gln Leu Glu Gln Ala Leu Glu Glu Met Lys Thr Asn His Cys Arg 180 185 190 Arg Val Val Arg Asn Ile Lys 195 <210> 3 <211> 174 <212> PRT <213> Homo sapiens <400> 3 Glu Phe Gly Arg Ile Ala Val Glu Phe Leu Arg Arg Gly Ala Asn Pro 1 5 10 15 Lys Ile Tyr Glu Gly Ala Ala Arg Lys Leu Asn Val Ser Ser Asp Thr 20 25 30 Val Gln His Gly Val Glu Gly Leu Thr Tyr Leu Leu Thr Glu Ser Ser 35 40 45 Lys Leu Met Ile Ser Glu Leu Asp Phe Gln Asp Ser Val Phe Val Leu 50 55 60 Gly Phe Ser Glu Glu Leu Asn Lys Leu Leu Leu Gln Leu Tyr Leu Asp 65 70 75 80 Asn Arg Lys Glu Ile Arg Thr Leu Leu Ser Glu Leu Ala Pro Ser Leu 85 90 95 Pro Ser Tyr His Asn Leu Glu Trp Arg Leu Asp Val Gln Leu Ala Ser 100 105 110 Arg Ser Leu Arg Gln Gln Ile Lys Pro Ala Val Thr Ile Lys Leu His 115 120 125 Leu Asn Gln Asn Gly Asp His Asn Thr Lys Val Leu Gln Thr Asp Pro 130 135 140 Ala Thr Leu Leu His Leu Val Gln Gln Leu Glu Gln Ala Leu Glu Glu 145 150 155 160 Met Lys Thr Asn His Cys Arg Arg Val Val Arg Asn Ile Lys 165 170 <210> 4 <211> 965 <212> DNA <213> mus musculus <220> <221> CDS <222> (44)... (640) <400> 4 ggcggggccg gcgccgggtg gcaaagtctg aagagccgct aaa atg ctg ctg gat 55 Met Leu Leu Asp 1 ttg tcc gag gag cac aag gag cac ttg gcc ttc ctg ccg caa gtg gac 103 Leu Ser Glu Glu His Lys Glu His Leu Ala Phe Leu Pro Gln Val Asp 5 10 15 20 act gca gtg gtc gcc gag ttc ggg agg atc gcc gtg gag ttc ctc cga 151 Thr Ala Val Val Ala Glu Phe Gly Arg Ile Ala Val Glu Phe Leu Arg 25 30 35 cgg ggc tca aac ccg aag atc tac gaa ggc gcc gcc aga aaa ctg aac 199 Arg Gly Ser Asn Pro Lys Ile Tyr Glu Gly Ala Ala Arg Lys Leu Asn 40 45 50 gtg agt agt gac act atc cag cat ggt gtg gaa gga tta acg tat ctc 247 Val Ser Ser Asp Thr Ile Gln His Gly Val Glu Gly Leu Thr Tyr Leu 55 60 65 ctc acc gag agc tca aag ctt atg att tct gaa ctg gat ttc caa gac 295 Leu Thr Glu Ser Ser Lys Leu Met Ile Ser Glu Leu Asp Phe Gln Asp 70 75 80 tct gtc ttt gtt ctg gga ttc tct gaa gaa cta aac aaa tta ttg ctt 343 Ser Val Phe Val Leu Gly Phe Ser Glu Glu Leu Asn Lys Leu Leu Leu 85 90 95 100 cag ctc tac ctg gac aac aga aag gag atc aga act att ctg aac gag 391 Gln Leu Tyr Leu Asp Asn Arg Lys Glu Ile Arg Thr Ile Leu Asn Glu 105 110 115 tta gca cct cgt ctt ccc agt tac cat agt ctt gag tgg cgg cta gat 439 Leu Ala Pro Arg Leu Pro Ser Tyr His Ser Leu Glu Trp Arg Leu Asp 120 125 130 gta cag ctt gca agc aga agt ctc cgg caa cag att aag cca gca gtg 487 Val Gln Leu Ala Ser Arg Ser Leu Arg Gln Gln Ile Lys Pro Ala Val 135 140 145 acc ata aag ctg cac ctc gat cag aat ggc gac cac agc act cat ttc 535 Thr Ile Lys Leu His Leu Asp Gln Asn Gly Asp His Ser Thr His Phe 150 155 160 ttg cag aca gac cca gct acc ctg ctt cat ttg gtt cag cag ctg gag 583 Leu Gln Thr Asp Pro Ala Thr Leu Leu His Leu Val Gln Gln Leu Glu 165 170 175 180 cag gcg tta gag gaa atg aaa aca aac cac tgc agg aga gta gtc cgc 631 Gln Ala Leu Glu Glu Met Lys Thr Asn His Cys Arg Arg Val Val Arg 185 190 195 agc atc aag tagctctgag gtttccttcc ttccagttgg agacactggc 680 Ser Ile Lys gtggcagtgg tacgtctgga ttcgtggagt ttctttccct gctcaggatg ttgaaatctt 740 gatcagaagc tgagccgcag ctccgttttg gtgctgaatg cggtcagctt cttgcaggtt 800 ggaaagcatt ttttacttca agtgtgtaaa gaggatgcac caactaagat ggatcaatac 860 tgctgatttc tgtggactct tcggacttgg atattttttt tatctacttt atttcctttg 920 ctcttgatca aaatttgaaa ataaaattca ctgttactac ttaga 965 <210> 5 <211> 199 <212> PRT <213> mus musculus <400> 5 Met Leu Leu Asp Leu Ser Glu Glu His Lys Glu His Leu Ala Phe Leu 1 5 10 15 Pro Gln Val Asp Thr Ala Val Val Ala Glu Phe Gly Arg Ile Ala Val 20 25 30 Glu Phe Leu Arg Arg Gly Ser Asn Pro Lys Ile Tyr Glu Gly Ala Ala 35 40 45 Arg Lys Leu Asn Val Ser Ser Asp Thr Ile Gln His Gly Val Glu Gly 50 55 60 Leu Thr Tyr Leu Leu Thr Glu Ser Ser Lys Leu Met Ile Ser Glu Leu 65 70 75 80 Asp Phe Gln Asp Ser Val Phe Val Leu Gly Phe Ser Glu Glu Leu Asn 85 90 95 Lys Leu Leu Leu Gln Leu Tyr Leu Asp Asn Arg Lys Glu Ile Arg Thr 100 105 110 Ile Leu Asn Glu Leu Ala Pro Arg Leu Pro Ser Tyr His Ser Leu Glu 115 120 125 Trp Arg Leu Asp Val Gln Leu Ala Ser Arg Ser Leu Arg Gln Gln Ile 130 135 140 Lys Pro Ala Val Thr Ile Lys Leu His Leu Asp Gln Asn Gly Asp His 145 150 155 160 Ser Thr His Phe Leu Gln Thr Asp Pro Ala Thr Leu Leu His Leu Val 165 170 175 Gln Gln Leu Glu Gln Ala Leu Glu Glu Met Lys Thr Asn His Cys Arg 180 185 190 Arg Val Val Arg Ser Ile Lys 195 <210> 6 <211> 174 <212> PRT <213> Mus musculus <400> 6 Glu Phe Gly Arg Ile Ala Val Glu Phe Leu Arg Arg Gly Ser Asn Pro 1 5 10 15 Lys Ile Tyr Glu Gly Ala Ala Arg Lys Leu Asn Val Ser Ser Asp Thr 20 25 30 Ile Gln His Gly Val Glu Gly Leu Thr Tyr Leu Leu Thr Glu Ser Ser 35 40 45 Lys Leu Met Ile Ser Glu Leu Asp Phe Gln Asp Ser Val Phe Val Leu 50 55 60 Gly Phe Ser Glu Glu Leu Asn Lys Leu Leu Leu Gln Leu Tyr Leu Asp 65 70 75 80 Asn Arg Lys Glu Ile Arg Thr Ile Leu Asn Glu Leu Ala Pro Arg Leu 85 90 95 Pro Ser Tyr His Ser Leu Glu Trp Arg Leu Asp Val Gln Leu Ala Ser 100 105 110 Arg Ser Leu Arg Gln Gln Ile Lys Pro Ala Val Thr Ile Lys Leu His 115 120 125 Leu Asp Gln Asn Gly Asp His Ser Thr His Phe Leu Gln Thr Asp Pro 130 135 140 Ala Thr Leu Leu His Leu Val Gln Gln Leu Glu Gln Ala Leu Glu Glu 145 150 155 160 Met Lys Thr Asn His Cys Arg Arg Val Val Arg Ser Ile Lys 165 170 <210> 7 <211> 15 <212> PRT <213> Homo sapiens <400> 7 Ser Ser Asp Thr Val Gln His Gly Val Glu Gly Leu Thr Tyr Leu 1 5 10 15 <210> 8 <211> 15 <212> PRT <213> Homo sapiens <400> 8 Val Leu Gly Phe Ser Glu Glu Leu Asn Lys Leu Leu Leu Gln Leu 1 5 10 15 <210> 9 <211> 15 <212> PRT <213> Homo sapiens <400> 9 Ile Arg Thr Leu Leu Ser Glu Leu Ala Pro Ser Leu Pro Ser Tyr 1 5 10 15 <210> 10 <211> 15 <212> PRT <213> Homo sapiens <400> 10 Leu Leu His Leu Val Gln Gln Leu Glu Gln Ala Leu Glu Glu Met 1 5 10 15 <210> 11 <211> 15 <212> PRT <213> Mus musculus <400> 11 Ser Ser Asp Thr Ile Gln His Gly Val Glu Gly Leu Thr Tyr Leu 1 5 10 15 <210> 12 <211> 15 <212> PRT <213> Mus musculus <400> 12 Val Leu Gly Phe Ser Glu Glu Leu Asn Lys Leu Leu Leu Gln Leu 1 5 10 15 <210> 13 <211> 15 <212> PRT <213> Mus musculus <400> 13 Ile Arg Thr Ile Leu Asn Glu Leu Ala Pro Arg Leu Pro Ser Tyr 1 5 10 15 <210> 14 <211> 15 <212> PRT <213> Mus musculus <400> 14 Leu Leu His Leu Val Gln Gln Leu Glu Gln Ala Leu Glu Glu Met 1 5 10 15 <210> 15 <211> 599 <212> DNA <213> Homo sapiens <220> <221>m1scfeature <222> (1)... (599) <223> n = A T C or G <400> 15 ggacagtgaa gatgctgctg gaattgtccg aggagcataa ggaacacctg gccttcctgc 60 ctcaagtgga cagcgcggtg gtcgccgagt ttgggcggat tgctgtggaa ttcctgagac 120 gcggcgcaaa cccaaaaatc tacgaaggcg ccgcagaaaa ctcaatgtga gtagtgacac 180 tgtccagcat ggtgtggaag gattaacgta tctcctcact gagagctcaa agctcatgat 240 ttctgaactg gatttccaag actctgtttt tgttctggga ttctctgaag aattaaacaa 300 attgttgctt cagctttatc tggacaacag aaaagagatc agaacgattc tgagtgaatt 360 ggcaccaagc cttcccagtt atcataacct tgaatggcga ctagatgtac agcttgcaag 420 tagaagtctc aggcaacaga ttaaccagca gtgactataa agctacacct taatcaaaat 480 ggagatcaca acaccaagtt ctgcagacag acccagccac cctgctccat ttggntcaca 540 atngaacaag cattggaaga gatgaagnca acccctgttg gagaattgtt gcaacatca 599 <210> 16 <211> 29 <212> PRT <213> Homo sapiens <400> 16 Arg Arg Gly Ala Asn Pro Lys Ile Tyr Glu Gly Ala Ala Arg Lys Leu 1 5 10 15 Asn Val Ser Ser Asp Thr Val Gln His Gly Val Glu Gly 20 25 <210> 17 <211> 23 <212> PRT <213> Homo sapiens <400> 17 Gln Gln Leu Glu Gln Ala Leu Glu Glu Met Lys Thr Asn His Cys Arg 1 5 10 15 Arg Val Val Arg Asn Ile Lys 20 <210> 18 <211> 45 <212> PRT <213> Homo spaiens <400> 18 Asn Gln Asn Gly Asp His Asn Thr Lys Val Leu Gln Thr Asp Pro Ala 1 5 10 15 Thr Leu Leu His Leu Val Gln Gln Leu Glu Gln Ala Leu Glu Glu Met 20 25 30 Lys Thr Asn His Cys Arg Arg Val Val Arg Asn Ile Lys 35 40 45 <210> 19 <211> 47 <212> PRT <213> Homo sapiens <400> 19 Thr Glu Ser Ser Lys Leu Met Ile Ser Glu Leu Asp Phe Gln Asp Ser 1 5 10 15 Val Phe Val Leu Gly Phe Ser Glu Glu Leu Asn Lys Leu Leu Leu Gln 20 25 30 Leu Tyr Leu Asp Asn Arg Lys Glu Ile Arg Thr Leu Leu Ser Glu 35 40 45 <210> 20 <211> 57 <212> PRT <213> Homo sapiens <400> 20 Thr Glu Ser Ser Lys Leu Met Ile Ser Glu Leu Asp Phe Gln Asp Ser 1 5 10 15 Val Phe Val Leu Gly Phe Ser Glu Glu Leu Asn Lys Leu Leu Leu Gln 20 25 30 Leu Tyr Leu Asp Asn Arg Lys Glu Ile Arg Thr Leu Leu Ser Glu Leu 35 40 45 Ala Pro Ser Leu Pro Ser Tyr His Asn 50 55 <210> 21 <211> 25 <212> PRT <213> Mus musculus <400> 21 Arg Arg Gly Ser Asn Pro Lys Ile Tyr Glu Gly Ala Ala Arg Lys Leu 1 5 10 15 Asn Val Ser Ser Asp Thr Ile Gln His 20 25 <210> 22 <211> 16 <212> PRT <213> Mus musculus <400> 22 Glu Glu Met Lys Thr Asn His Cys Arg Arg Val Val Arg Ser Ile Lys 1 5 10 15 <210> 23 <211> 57 <212> PRT <213> Mus musculus <400> 23 Thr Glu Ser Ser Lys Leu Met Ile Ser Glu Leu Asp Phe Gln Asp Ser 1 5 10 15 Val Phe Val Leu Gly Phe Ser Glu Glu Leu Asn Lys Leu Leu Leu Gln 20 25 30 Leu Tyr Leu Asp Asn Arg Lys Glu Ile Arg Thr Ile Leu Asn Glu Leu 35 40 45 Ala Pro Arg Leu Pro Ser Tyr His Ser 50 55 <210> 24 <211> 27 <212> PRT <213> Homo sapiens <400> 24 Ser Arg Ser Leu Arg Gln Gln Ile Lys Pro Ala Val Thr Ile Lys Leu 1 5 10 15 His Leu Asp Gln Asn Gly Asp His Ser Thr His 20 25 <210> 25 <211> 48 <212> DNA <213> Homo sapiens <400> 25 gtctgggttc gctactcgag gcggccgcta tttttttttt tttttttt 48 <210> 26 <211> 448 <212> DNA <213> Mus musculus <400> 26 ggcggggccg gcgccgggtg gcaaagtctg aagagccgct aaaatgctgc tggatttgtc 60 cgaggagcac aaggagcact tggccttcct gccgcaagtg gacactgcag tggtcgccga 120 gttcgggagg atcgccgtgg agttcctccg acggggctca aacccgaaga tctacgaagg 180 cgccgccaga aaactgaacg tgagtagtga cactatccag catggtgtgg aaggattaac 240 gtatctcctc accgagagct caaagcttat gatttctgaa ctggatttcc aagactctgt 300 ctttgttctg ggattctctg aagaactaaa caaatgattg cttcagctct acctggacaa 360 cagaaaggag atcagaacta ttctgaacga gttagcacct cgtcttccca gttaccatag 420 tcttgagtgg cggctagatg tacagctt 448. |
Description:
INTERNATIONAL SEARCH REPORT pterr al Application No PCT/US 00/17698 C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A DATABASE EMBL'Online ! 1-14 764222, accession number AA764222, 28 January 1998 (1998-01-28) M. MARRA ET AL:"The WashU-HHMI mouse EST project. vv45g03. r1 Soares 2NbMT musculus cDNA clone IMAGE: 1225396 5', mRNA sequence" XP002158470 "99,56% identity in 461 nt overlap with sequence ID no. 4 (60-520: 2-461)" abstract &UNPUBLISHED, A DATABASE EMBL'Online ! 1-14 HSAA82767, accession number AA082767, 29 November 1996 (1996-11-29) L. HILLIER ET AL :"zn41a02. rl Stratagene endothelial cell 937223 Homo sapiens cDNA clone IMAGE: 549962 5', mRNA sequence" XP002158471 "97,69% identity in 606 nt overlap with sequence no. l (22-627: 1-599)" abstract &L. HILLIER ET AL:"Generation and analysis of 280,000 human expressed sequence tags" GENOMERESEARCH, vol. 6, no. 9,1996, pages 807-828, XP000914615 A DATABASE EMBL'Online ! 1-14 entry AA590825, accession number AA590825, 18 September 1997 (1997-09-18) M. MARRA ET AL:"The WashU-HHMI mouse EST project" XP002158476 "99,8% identity in 522 nt overlap with sequence ID no. 4 (38-559: 1-522)" abstract &UNPUBLISHED, A DATABASE EMBL'Online ! 1-14 C78443, accession number c78443, 13 October 1997 (1997-10-13) M. S. H. KO ET AL:"Mus musculus 3.5-dpc blastocyst cDNA 3'-end sequence" XP002158473 "98,99% identity in 596 nt overlap with sequence ID no. 4. Reverse orientation. (960-365: 1-594)" abstract &UNPUBLISHED, 2 FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 Continuation of Box 1. 2 Claims Nos.: 5 and 13 partially Claim 5 and claim 13 refer to an antagonist of the polypeptide Zalpha36 without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported. No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved. A partial search has been carried out as far as the antagonist is an antibody to the polypeptide Zalpha36 (as defined in the claims 6 and 14). The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1 (e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.
Previous Patent: CATALYTICALLY ACTIVE RECOMBINANT MEMAPSIN AND METHODS OF USE THEREOF
Next Patent: INHIBITORS OF MEMAPSIN 2 AND USE THEREOF
Next Patent: INHIBITORS OF MEMAPSIN 2 AND USE THEREOF